Indivior lifts FY guidance as Q3 profits, revenue jump
(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.
Read moreWed, 08th Apr 2020 10:11
(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.
Read more(Sharecast News) - The Financial Mail on Sunday's Midas column told readers to buy shares of Light Science Technologies, pointing out the benefits of the company's technology for health, climate and the UK more economy.
Read moreLONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint
Read more(Sharecast News) - Indivior revealed on Wednesday that non-executive director Mark Stejbach had acquired 36,000 ordinary shares in the FTSE 250-listed pharmaceuticals business.
Read moreDIRECTOR DEALINGS: 3i team buy; Scopia trims Indivior stake further
Read moreDIRECTOR DEALINGS: IntegraFin COO sells; Chaarat Gold chair buys
Read moreDIRECTOR DEALINGS: Scopia slims 16% Indivior stake as chair buys
Read moreDIRECTOR DEALINGS: Robert Walters CEO sells GBP2.8 million in shares
Read moreIN BRIEF: Indivior to commence USD100 million share repurchase program
Read moreIN BRIEF: Indivior unveils profit hike and USD100 million buyback
Read moreLONDON MARKET MIDDAY: Investors cheer dividend hikes and buyback plans
Read more(Sharecast News) - Speciality pharmaceuticals company Indivior reiterated its upgraded guidance for 2021 on Thursday, and announced the start of a $100m (£71.71m) share buyback programme, as its first-half net revenue rose to $381m from $303m year-on-year.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIndivior agrees new loan facilities of USD250 million maturing in 2026
Read more(Sharecast News) - Pharmaceutical firm Indivior said on Thursday that it had entered into an amendment to reprice and extend the maturity of $250.0m worth of term loan facilities.
Read more